Earnings Releases·Nov 12, 2026, 4:05 PM ET

Prime Medicine — Third Quarter 2026 Earnings Summary

Total revenue reached $4.2 million for Q3 2026, up from $1.2 million in the prior year period, while net loss narrowed to $39.0 million from $50.6 million, driven by reduced R&D and G&A expenses.
Cash and equivalents declined to $74.8 million as of September 30, 2026, from $191.4 million at year-end 2025, though a November 2026 public offering raised $134.7 million in net proceeds to fund operations through 2027.
Key clinical milestones include the dosing of the first patient in the PM577a (Wilson disease) Phase 1/2 trial in October 2026 and FDA clearance of the PM647 (AATD) IND in September 2026, with initial clinical data for both programs expected in 2027.
A Biologics License Application (BLA) for PM359 (Chronic Granulomatous Disease) is scheduled for submission in the first half of 2027, and the company anticipates the FDA's draft guidance on individualized genome editing may expand therapy opportunities.
The resolution of an arbitration dispute with Beam Therapeutics in July 2026 confirmed PM647 falls within Prime Medicine's licensed field, solidifying the company's liver franchise strategy.